Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

BACKGROUND: Achieving control of glycated hemoglobin (HbA1c), blood pressure (BP), and body weight (BW) remains a challenge for most patients with type 2 diabetes mellitus (T2DM). In clinical trials, canagliflozin (CANA), an inhibitor of sodium-glucose co-transporter 2, has shown significant improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysham, Carol H., Lefebvre, Patrick, Pilon, Dominic, Ingham, Mike, Lafeuille, Marie-Hélène, Emond, Bruno, Kamstra, Rhiannon, Chow, Wing, Pfeifer, Michael, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465542/
https://www.ncbi.nlm.nih.gov/pubmed/28595617
http://dx.doi.org/10.1186/s12902-017-0180-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465542/
https://www.ncbi.nlm.nih.gov/pubmed/28595617
http://dx.doi.org/10.1186/s12902-017-0180-8

Ejemplares similares